Our news

  • Implications for practice1. Pitavastatin causes a linear dose‐response reduction in the per cent change from control of blood LDL cholesterol, total cholesterol and blood triglycerides. There is no dose‐response relationship for HDL cholesterol which is increased by 4% on average for all doses. This effect on HDL is not different...
    June 19 2020
  • Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Spring 2020) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter...
    June 18 2020
  • Conclusions:There is an implicit assumption that early detection fo hypertension through screening can reduce the burden of morbidity and mortality, but this assumption has not been tested in rigorous research studiesHigh-quality evidence from RCTs or programmatic evidence from NRCTs on the effectiveness and costs or harms of different screening...
    June 12 2020
  • Plain language conclusions:It may be safe to stop antihypertensive medications in older people who are taking the medication for high blood pressure or primary prevention of heart diseaseOlder adults should not stop any of their medications with out talking to a healthcare professionalFuture studies should include older adults who are taking...
    June 12 2020
  • Introducing the Cochrane Circulation & Breathing NetworkWatch the video: https://buff.ly/2XlwLJEThis network covers the work of  Cochrane Hypertension, Cochrane Airways, Cochrane Heart, Cochrane Stroke, and Cochrane Vascular
    July 8 2019
  • Conclusions:Blood pressure-lowering therapy in people with hypertension 60 years and older reduced death, strokes, and heart attacksBenefit was similar if both upper and lower blood pressure numbers were elevated and if only the upper number was elevatedFirst-line treatment used in most studies was a thiazideMagnitude of benefit in cardiovascular...
    July 8 2019
  • Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Winter 2020) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter...
    February 28 2019
  • First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertensionCompared to first-line renin angiotensin system (RAS inhibitors), first-line thiazides reduce heart failure (HF) and strokeCompared with calcium channel blockers (CCBs), RAS inhibitors reduce HF, but increase stroke; the...
    November 14 2018
  • 18thSeptember 2018Authors’ response to Dr. Swapnil Hiremath’s critical remarks on our recently updated Cochrane systematic review Luis Carlos Saiz1, Javier Gorricho2, Javier Garjón3, Mª Concepción Celaya3, Juan Erviti1, Leire Leache11 Unit of Innovation and Organization, Navarre Health Service, Pamplona, Spain.2 Planning, Evaluation...
    September 3 2018
  • Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Autumn 2018) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter...
    July 24 2018

Pages

Subscribe to Our news